Triapine with temozolomide for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial is testing a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back. The goal is to see if this combination can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a brain tumor that has come back (recurrent glioblastoma).
- You have had 3 or fewer prior treatments for your tumor.
- You are able to have an MRI with contrast.
- You are on a stable or lower dose of steroids (like dexamethasone) for at least 7 days before starting.
- You are not pregnant or nursing, and you agree to use two forms of birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
This trial tests two new drugs together: Actimab-A (a targeted therapy) and cemiplimab (an immunotherapy that helps your immune system fight cancer). It is for people whose glioblastoma has returned after initial treatment, and the goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (temozolomide and dexbrompheniramine) to treat high-grade gliomas that have come back after standard treatment. The goal is to see if this combination can help control the tumor or slow its growth.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.